2. Search Result
Search Result
Results for "

CPM

" in MedChemExpress (MCE) Product Catalog:

9

Inhibitors & Agonists

2

Fluorescent Dye

2

Peptides

1

Natural
Products

2

Recombinant Proteins

1

Isotope-Labeled Compounds

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-D0069
    CPM

    		Fluorescent Dye Others Cancer
    CPM is a maleimide derivative, acting as a blue fluorescent thiol-reactive dye. The excitation/emission maxima is 384/470 nm .
    CPM
  • HY-13010
    Laquinimod
    2 Publications Verification

    ABR-215062

    		 NF-κB Apoptosis Inflammation/Immunology
    Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator which prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has?the?potential?for relapsing remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases?research .
    Laquinimod
  • HY-13010S
    Laquinimod-d5

    ABR-215062-d5

    		 Isotope-Labeled Compounds Apoptosis NF-κB Inflammation/Immunology
    Laquinimod-d5 (ABR-215062-d5) is deuterium labeled Laquinimod. Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator that prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing-remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research .
    Laquinimod-d5
  • HY-P10057
    cpm-1285

    		Apoptosis Cancer
    cpm-1285 induces apoptosis by functionally blocking intracellular Bcl-2 and related death antagonists. cpm-1285 shows strong binding potency to Bcl-2 with an IC50 value of 130 nM. cpm-1285 reduces tumor burden in mice .
    cpm-1285
  • HY-P10058
    cpm-1285m

    		Biochemical Assay Reagents Cancer
    cpm-1285m is a cell-permeable mutated peptide analogue of cpm-1285 (Bcl-2 inhibitory peptide). cpm-1285m contains a single substitution of alanine for Leu-151, and exhibits a decrease in Bcl-2 binding affinity with a reduction in IC50 of ∼15-fold. cpm-1285m can be used as a control of cpm-1285 .
    cpm-1285m
  • HY-RS03100
    CPM Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    CPM Human Pre-designed siRNA Set A contains three designed siRNAs for CPM gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CPM Human Pre-designed siRNA Set A
    CPM Human Pre-designed siRNA Set A
  • HY-D2376
    BH-Vis

    		Fluorescent Dye Cancer
    BH-Vis is a two-photon fluorescent probe that inhibits cell plasma membrane (CPM). BH-Vis has great potential to accurately identify pyroptosis at the cellular level during AAA development in the mouse abdominal aortic aneurysm AAA model .
    BH-Vis
  • HY-W062904
    Laquinimod sodium

    ABR-215062 sodium

    		 NF-κB Apoptosis Neurological Disease Inflammation/Immunology
    Laquinimod (ABR-215062) sodium, an orally available carboxamide derivative, is a potent immunomodulator which prevents neurodegeneration and inflammation in the central nervous system. Laquinimod sodium reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod sodium has the potential for relapsing remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research .
    Laquinimod sodium
  • HY-13010R
    Laquinimod (Standard)

    		NF-κB Apoptosis Inflammation/Immunology
    Laquinimod (Standard) is the analytical standard of Laquinimod. This product is intended for research and analytical applications. Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator which prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research .
    Laquinimod (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: